ACE and COVID-19: A Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAPCAP), a randomized trial of ARBs or ACE inhibitors versus usual care in patients hospitalized for acute COVID-19, was stopped early after a planned interim analysis because of significantly increased mortality and acute kidney injury rates in the ARB arm compared to usual care among the critically ill patient stratum.